One such use case includes the work GLOphotonics is doing with regard to the treatment of a variety of blood vessel disorders such as removal of unwanted leg veins and facial capillaries. Another noteworthy use case where GLO technology has proven ideal, is next generation machines for ophthalmology surgery.

“Unlike conventional fibres where the cladding is solid, we have designed a fibre where the cladding is microstructured to specifically confine and guide light in a hollow channel”

So, what sets GLO technology apart from its solid core counterparts in the market? Solid core fibres are notorious for getting damaged too quickly when high energy light propagates through them. GLO’s PMC not only remains unscathed during propagation, but it also transmits the light with infinitesimal energy loss. “Even if there is no need for high energy light, solid core fibres will still distort the temporal integrity of the pulse due to nonlinearity effects such as Raman and the Kerr,” stresses Benabid. The technology of the PMC allows users to control the pressure of the gas and evacuate air to be rid of the issues of non-linearity. Furthermore, eliminating non-linearity allows pulses to be compressed down to a tenth of a femtosecond—facilitates precise heating, another factor that makes GLO’s PMC technology invaluable to the world of medicine.

Surging Ahead with Momentum

There is little doubt that a bright future awaits GLOphotonics, a company that continues to earn the acclaim and faith of Europe’s photonics industry. Over the last seven months, the startup has received Series A funding from global high-tech companies such as DMG Mori Seiki Co and TRUMPF Lasertechnik GmbH + Co. KG. These investments will allow GLOphotonics to enter the next phase of its business, recruit top talent, complete a state-of-the-art production facility, and address newer industrial markets.

One such emerging application is bioimaging, a complex field that requires the delivery of specific light (in multiple lines) to visualise biological activity within a timeframe. If there is a technology equipped to handle the application, it is GLOphotonics. After all, its PMC technology’s ability to create multi-laser lines was tested by the National Institute of Health (NIH), an achievement that Benabid is still proud of. “The fact that we were the first to provide any colour and multi-line lasers is still appreciated by the medical industry,” he says.

While GLOphotonics does not have direct access to the end-user, it will continue to collaborate with major manufacturers and system integrators across the world to bolster its global network. The company is also committed to providing samples, application notes, and reference designs to its target markets to help them integrate GLO components into their new products. Working closely with its partners, GLO will also generate application examples to highlight the features and benefits of its proprietary PMC technology.

All the success not withstanding, Benabid takes pride in the fact that GLOphotonics and its solutions’ ingenuity prove beyond helpful to institutions looking to battle cancer. As a matter of fact, GLOphotonics’ technology has also been used by NASA in their space expeditions!

Its technology is changing the way the world views optical fibre technology—from simple fibres for communications to sophisticated photonic crystal fibre technology that saves lives.